Big Sky Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2005



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Translational Medicine in Autoimmunity (A4)


Organizer(s) Lloyd H. Kasper, David A. Hafler and Lucienne Chatenoud
January 8—13, 2005
Big Sky Resort • Big Sky, Montana USA
Abstract Deadline: Sep 16, 2004
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Nov 8, 2004

Supported by The Director's Fund

Summary of Meeting:
Recent advances in the understanding of basic mechanisms of autoimmune disease have led to the development of reagents that can potentially interfere with the disease process and limit disease progression. Some of these therapeutics have already been proven effective in the treatment of autoimmune conditions. This meeting will focus on the use of novel therapeutics for the treatment and management of several autoimmune diseases including multiple sclerosis, inflammatory bowel disease, diabetes, systemic lupus and rheumatoid arthritis. Information will be presented that highlights new findings that "bridge" the gap between bench and bedside. Particular emphasis will be placed on the translational therapeutics between pre-clinical and Phase I/II research. This will include such topics as blocking of co-stimulation, T cell trafficking, Th1 cytokine production (IL-12 and IL-23), T cell receptor vaccination, islet cell transplantation, chemokine antagonists and signal transduction pathway inhibitors. The application of these novel approaches to specific disease process will be examined and will provide insight into clinical disease management.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SATURDAY, JANUARY 8

15:00—19:30
Registration

Lower Atrium
18:30—19:30
Refreshments

Lower Atrium
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Jefferson
Ravinder Maini, Imperial College London, UK
Biological and Clinical Lessons Learned from TNF Blockade in Man


SUNDAY, JANUARY 9

07:00—08:00
Breakfast

Madison/Gallatin
08:00—11:00
Immunmodulation in Diabetes
Meeting has ended...abstracts no longer viewable online.

Jefferson
Megan Sykes, Massachusetts General Hospital, USA
Induction of Allotolerance and Reversal of Autoimmune Diabetes via Mixed Chimerism

Matthias G. von Herrath, Novo Nordisk and La Jolla Institute for Allergy and Immunology, USA
Viral Infections can Abrogate Autoimmunity by Inducing Apoptosis of Autoaggressive T Cells

* Jeffrey A. Bluestone, University of California, San Francisco, USA
Immune Regulation in Diabetes - Balancing the Good with the Bad

George S. Eisenbarth, University of Colorado Health Sciences Center, USA
Prediction of Organ Specific Autoimmunity

Manuela Battaglia, TIGET, Telethon Institute for Gene Therapy, Italy
Short Talk: Rapamycin and IL-10 Block Diabetes and Induce Long Term Tolerance in NOD Mice via both CD4+CD25+ Tr and Tr1 Cells

09:20—09:40
Coffee Break

Lower Atrium
11:00—13:00
Poster Setup

Madison/Gallatin
13:00—22:00
Poster Viewing

Madison/Gallatin
16:30—17:00
Coffee & Snacks Available

Lower Atrium
17:00—19:00
Peptide Blocking and Prevention of Autoimmunity
Meeting has ended...abstracts no longer viewable online.

Jefferson
* Stephen D. Miller, Northwestern University Medical School, USA
Treatment of Established Relapsing EAE Using Peptide-Specific Tolerance: Cellular and Molecular Mechanisms

Jan D. Lünemann, University Hospital Zurich, Switzerland
Short Talk: Ubiquitous Viruses Activate Cerebrospinal Fluid T Cell Clones in Multiple Sclerosis

Lawrence Steinman, Stanford University, USA
Antigen Specific Therapy of Autoimmune Disease: DNA Vaccines and APL Therapy in Humans with MS and IDDM

19:00—20:00
Social Hour

Madison/Gallatin
19:30—22:00
Poster Session 1

Madison/Gallatin

MONDAY, JANUARY 10

07:00—08:00
Breakfast

Madison/Gallatin
08:00—11:00
Therapeutic Intervention in Multiple Sclerosis
Meeting has ended...abstracts no longer viewable online.

Jefferson
Samia J. Khoury, Brigham and Women's Hospital, USA
Costimulatory Signal Blockade from Bench to Bedside

Randolph J. Noelle, Dartmouth College, USA
Dendritic Cells as Targets in MS

Howard L. Weiner, Brigham and Women’s Hospital, Harvard Medical School, USA
Oral Tolerance in MS

Amit Bar-Or, University of Pennsylvania, USA
Impact of MS Therapies on Immune-Neural Interactions

* Lloyd H. Kasper, Geisel School of Medicine at Dartmouth, USA
Short Talk: Blocking the IL-12/23p40 Cytokine Pathway in Multiple Sclerosis

09:20—09:40
Coffee Break

Lower Atrium
11:15—13:00
Poster Setup

Madison/Gallatin
13:00—22:00
Poster Viewing

Madison/Gallatin
15:30—17:00
Workshop 1: Selected Oral Abstracts

Jefferson
* Stephen L. Hauser, University of California, San Francisco, USA

* Samia J. Khoury, Brigham and Women's Hospital, USA

James Varani, University of Michigan, USA
In vitro Approach to the Preclinical Assessment of Potential Therapeutics for Psoriasis

Paul W. Thompson, GlaxoSmithKline, UK
IL-10 is a PPAR-gamma Target Gene

Richard H. Scheuermann, J. Craig Venter Institute, USA
Immunology Data Integration through the ImmPort Data Model

Emma L. Masteller, Inovio Pharmaceuticals, USA
Therapeutic Potential of Endogenous Islet-Specific CD4+CD25+ Foxp3+ Regulatory T Cells Expanded from Nonobese Diabetic Mice

Laurie A. Minns, GlaxoSmithKline-Biologicals, USA
A Single Zwitterionic Polysaccharide from Bacteroides fragilis Prevents T. gondii-Induced Th1 Ileitis

Michael R. Ehrenstein, University College London, UK
Characterization of Regulatory T Cells in Rheumatoid Arthritis Before and After Treatment with Anti-TNFalpha Therapy

17:00—17:30
Coffee & Snacks Available

Lower Atrium
17:00—19:00
B Cell Disruption in Autoimmunity
Meeting has ended...abstracts no longer viewable online.

Jefferson
* Stephen L. Hauser, University of California, San Francisco, USA
Blocking B Cell Function

Jonathan C.W. Edwards, University College London, UK
Depleting B Cells in Rheumatoid Arthritis

Yulia Vugmeyster, Genentech, Inc., USA
Short Talk: Characterization of BR3-Fc-Mediated B-Cell Reduction in Cynomolgus Monkeys

Loren D. Erickson, Dartmouth Medical School, USA
Short Talk: B Cell Receptor Affinity is a Determinant in B Cell Lifespan and Fate

19:00—20:00
Social Hour

Madison/Gallatin
19:30—22:00
Poster Session 2

Madison/Gallatin

TUESDAY, JANUARY 11

07:00—08:00
Breakfast

Madison/Gallatin
08:00—11:00
Immunmodulation of Inflammatory Bowel Disease
Meeting has ended...abstracts no longer viewable online.

Jefferson
Evan M. Beckman, Novartis Institutes for BioMedical Research, USA
Blocking Alpha 4 Integrin in Crohn's Disease

Sander J. Van Deventer, Academic Medical Center, Netherlands
Inhibition of MAP Kinase for Treatment of IBD

* Richard S. Blumberg, Brigham and Women's Hospital, USA
Blocking PPARgamma and IBD

Warren Strober, National Institutes of Health, USA
Anti-IL-12 is an Effective Approach to the Treatment of the Th1-Mediated Inflammation in Crohn’s Disease

Claire L. Langrish, Takeda San Francisco, USA
Short Talk: Differential Contributions of IL-12 and IL-23 to Autoimmune Inflammation

09:20—09:40
Coffee Break

Lower Atrium
15:30—17:00
Workshop 2: Regulatory T Cells

Jefferson
* Randolph J. Noelle, Dartmouth College, USA

* Sander J. Van Deventer, Academic Medical Center, Netherlands

Brian T. Fife, University of Minnesota, USA
Antigen-Specific Tolerance as a Treatment for Autoimmune Diabetes in NOD Mice

Shuiping Jiang, King's College London, UK
Selection and Expansion of Antigen-Specific CD4+CD25+ Regulatory T Cells: Potential Reagents for Adoptive Cell Therapy

Benedikt Fritzsching, German Cancer Research Center, Germany
Sensitivity of Regulatory T Cells to Apoptosis and its Translation to Multiple Sclerosis

David A. Horwitz, University of Southern California, USA
Infectious Tolerance in vivo: The Transfer of Antigen-Specific Regulatory T Cells Generated ex-vivo Induces Recipient CD4+CD25+ Cells with Similar Specific Suppressive Activity

Karin Loser, University of Muenster, Germany
Treatment of Murine Allergic Contact Hypersensitivity and Systemic Autoimmunity with in vitro Generated Regulatory T Cells

Xavier Valencia, Novo Nordisk, USA
CD4+CD25+ T Regulatory Cell Function in Rheumatoid Arthritis

Kristin V. Tarbell, NIDDK, National Institutes of Health, USA
Islet-Specific CD4+CD25+ Regulatory T Cells can be Expanded from a Polyclonal Repertoire by Using Dendritic Cells

17:00—17:30
Coffee & Snacks Available

Lower Atrium
17:00—19:15
Modulating the Regulatory Response
Meeting has ended...abstracts no longer viewable online.

Jefferson
Ethan M. Shevach, NIAID, National Institutes of Health, USA
Activation and Modulation of T Regulatory Function in vivo

* Lucienne Chatenoud, INSERM U1151, Hôpital Necker-Enfants Malades, France
Regulation in Autoimmunity

David A. Hafler, Yale University School of Medicine, USA
Regulatory T Cells in MS

Joan Goverman, University of Washington, USA
Regulating the T Cell Response To Myelin Basic Protein

19:15—20:15
Social Hour

Madison/Gallatin

WEDNESDAY, JANUARY 12

07:00—08:00
Breakfast

Madison/Gallatin
08:00—11:00
Therapeutic Intervention in Lupus and Rheumatoid Arthritis
Meeting has ended...abstracts no longer viewable online.

Jefferson
Robert H. Carter, NIAMS, National Institutes of Health, USA
Understanding B Cell Activation

* Betty Diamond, Feinstein Institute for Medical Research, USA
Regulating Autoreactive B Cells

Anne Davidson, Feinstein Institute for Medical Research, USA
Costimulatory Blockade in Murine SLE

Cornelia M. Weyand, Emory University School of Medicine, USA
T Cells in Rheumatoid Arthritis

Mieke Boots, NV Organon, Netherlands
Short Talk: Functional Characterization of a Rheumatoid Arthritis-Associated Epitope Using T Cell Hybridomas Recognizing the HLA-DR4(B1*0401)/HC gp-39 (263-275) Complex

09:20—09:40
Coffee Break

Lower Atrium
16:30—17:00
Coffee & Snacks Available

Lower Atrium
17:00—19:00
Gene Therapy in Autoimmunity
Meeting has ended...abstracts no longer viewable online.

Jefferson
* Alan Tyndall, University Hospital Basel, Switzerland
Stem Cells Treatment of Severe Autoimmune Disease

Carrie D. Beal, Cleveland Clinic Foundation, USA
Short Talk: Amelioration of Established EAE by an MHC Anchor Substituted Variant of PLP 139-151

19:00—20:00
Social Hour

Madison/Gallatin
20:00—23:00
Entertainment

Madison/Gallatin

THURSDAY, JANUARY 13

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13-AI063786-01




We gratefully acknowledge additional support for this conference from:

Crohn's & Colitis Foundation of America JDRF
National Multiple Sclerosis Society Novartis Institutes for BioMedical Research

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Biogen Idec


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676